- Home
- / Endonovo Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Endonovo Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0
2024-10-29
Market Capitalization
$396.8 K
2024-10-29
Revenue
$135.4 K
FY, 2022
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45.5K | 30.6K | 4.3K | 83.3K | 310.2K | 165.8K | 73.1K | 135.4K | ||
| Cost of goods sold | 2.2K | 12.9K | 93.4K | 65.4K | 15.0K | 10.0K | ||||
| Gross profit | 2.1K | 70.3K | 216.8K | 100.4K | 58.1K | 125.4K | ||||
| Gross profit margin, % | 49.3% | 84.5% | 69.9% | 60.6% | 79.5% | 92.6% | ||||
| Operating expense total | 2.6M | 115.2K | 4.2M | 4.0M | 3.0M | 2.3M | 3.4M | |||
| EBIT | (95.5K) | (1.7M) | (2.6M) | (5.4M) | (4.6M) | (4.2M) | (3.8M) | (2.9M) | (2.2M) | (3.3M) |
| EBIT margin, % | -209.7% | -5697.5% | -60132.7% | -4995.3% | -1228.1% | -1756.5% | -3045.7% | -2411.7% | ||
| Interest expense | 2.2K | 113.5K | 1.5M | 2.4M | 5.8M | 5.2M | 17.0K | 941.6K | 1.3M | |
| Pre tax profit | (93.3K) | (1.9M) | (6.8M) | (5.3M) | (10.8M) | (6.4M) | (17.3M) | (395.6K) | (3.1M) | (18.5M) |
| Income tax expense | 800.0 | |||||||||
| Net Income | (94.1K) | (1.9M) | (6.8M) | (5.3M) | (10.8M) | (6.4M) | (17.3M) | (395.6K) | (3.1M) | (18.5M) |